Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy

Journal of the American College of Cardiology

Volumn 41, Issue 10, 2003, Pages 1776-1782

  Crilley, Jenifer G ^a,b,d   Boehm, Ernest A ^b   Blair, Edward ^a   Rajagopalan, Bheeshma ^a   Blamire, Andrew M ^a   Styles, Peter ^a   McKenna, William J ^c   Östman Smith, Ingegerd ^a   Clarke, Kieran ^b   Watkins, Hugh ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE PHOSPHATE; MYOSIN BINDING PROTEIN C; MYOSIN HEAVY CHAIN; PHOSPHORUS 31; TROPONIN T;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOENERGY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENERGY METABOLISM; FEMALE; GENE MUTATION; GENOTYPE; HEART LEFT VENTRICLE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; PRIORITY JOURNAL; SARCOMERE; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 0038701678     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)03009-7     Document Type: Article

References (35)

1. Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subiects in the CARDIA study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995;92:785-9.
2. Geisterfer-Lowrance AA, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain missense mutation. Cell 1990;62:999-1006.
3. Thierfelder L, Watkins H, MacRae C, et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 1994;77:701-12.
4. Watkins H, Connor D, Thierfelder L, et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet 1995;11:434-7.
5. Bonne G, Carrier L, Richard P, Hainque B, Schwartz K. Familial hypertrophic cardiomyopathy: from mutations to functional defects. Circ Res 1998;83:580-93.
6. Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol 2001;33:655-70.
7. Moolman JC, Corfield VA, Posen B, et al. Sudden death due to troponin T mutations. J Am Coll Cardiol 1997;29:549-55.
8. Redwood CS, Moolman-Smook JC, Watkins H. Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. Cardiovasc Res 1999;44:20-36.
9. Sweeney HL, Feng HS, Yang Z, Watkins H. Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function. Proc Natl Acad Sci U S A 1998;95:14406-10.
10. Spindler M, Saupe KW, Christe ME, et al. Diastolic dysfunction and altered energetics in the αMHC403/+ mouse model of familial hypertrophic cardiomyopathy. J Clin Invest 1998;101:1775-83.
11. Lodi R, Cooper JM, Bradley JL, et al. Deficit of in vivo mitochondrial ATP production in patients with Friedreichs ataxia. Proc Natl Acad Sci U S A 1999;96:11492-5.
12. Silvestri G, Bertini E, Servidei S, et al. Maternally inherited cardiomyopathy: a new phenotype associated with the A to G at nt.3243 of mitochondrial DNA (MELAS mutation). Muscle Nerve 1997;20:221-5.
13. Radda GK. The use of NMR spectroscopy for the understanding of disease. Science 1986;233:640-5.
14. Watkins H, Rosenzweig A, Hwang DS, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992;326:1108-14.
15. Niimura H, Bachinski LL, Sangwatanaroj S, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998;338:1248-57.
16. Crilley JG, Boehm EA, Rajagopalan B, et al. Magnetic resonance spectroscopy evidence of abnormal cardiac energetics in Xp21 muscular dystrophy. J Am Coll Cardiol 2000;36:1953-8.
17. Blamire AM, Rajagopalan B, Radda GK. Measurement of myocardial pH by saturation transfer in man. Magn Reson Med 1999;41:198-203.
18. Neubauer S, Horn M, Cramer M, et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997;96:2190-6.
19. Blair E, Price SJ, Baty CJ, et al. Mutations in cis can confound genotype-phenotype correlations in hypertrophic cardiomyopathy. J Med Genet 2001;38:385-8.
20. McKenna WJ, Spirito P, Desnos M, et al. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart 1997;77:130-2.
21. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1998;97:2536-42.
22. Lamb HJ, Beyebacht HP, van der Laarse A, et al. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation 1999;99:2261-7.
23. 31P magnetic resonance spectroscopy study. Cardiovasc Res 2001;52:111-9.
24. Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM. Intracellular compartmentation, structure, and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the phosphocreatine circuit for cellular energy homeostasis. Biochem J 1992;281:21-40.
25. Kalsi KK, Smolenski RT, Pritchard RD, et al. Energetics and function of the failing human heart with dilated or hypertrophic cardiomyopathy. Eur J Clin Invest 1999;29:469-77.
26. Tian R, Musi N, D'Agostino J, et al. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 2001;104:1664-9.
27. Shen W, Asai K, Uechi M, et al. Progressive loss of myocardial ATP due to a loss of total purines during the development of human heart failure in dogs. Circulation 1999;100:2113-8.
28. Cuda G, Fananapazir L, Zhu WS, Sellers JR, Epstein ND. Skeletal muscle expression and abnormal function of beta-myosin in hypertrophic cardiomyopathy. J Clin Invest 1993;91:2861-5.
29. Tyska MJ, Hayes E, Gierat M, et al. Single molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopthy. Circ Res 2000;86:737-44.
30. Montgomery DE, Tardiff JC, Chandra M. Cardiac troponin T mutations: correlation between the type of mutation and the nature of myofilament dysfunction in transgenic mice. J Physiol 2001;536:583-92.
31. Seppet EK, Kambre T, Sikk P, et al. Functional complexes of mitochondria with Ca, Mg ATPases of myofibrils and sarcoplasmic reticulum in muscle cells. Biochem Biophys Acta 2001;1504:379-95.
32. Blair E, Redwood C, Ashrafian H, et al. Mutations in the γ2 subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 2001;10:1215-20.
33. Gollob MH, Green MS, Tang AS-L, et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 2001;344:1823-31.
34. Arad M, Benson DW, Perez-Atayde AR, et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 2002;109:357-62.
35. Hardie DG, Carling D. The AMP-activated protein kinase - fuel gauge of the mammalian cell? Eur J Biochem 1997;246:259-73.